Background Optimal antiplatelet monotherapy during the chronic maintenance period in
patients who undergo coronary stenting is unknown. We aimed to compare head to head the …

Background: Long-term outcomes of antiplatelet monotherapy in patients who receive
percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal …

Background Despite the use of aspirin, there is still a risk of ischaemic events after
percutaneous coronary intervention (PCI). We aimed to find out whether, in addition to …

Background The potential benefits and risks of the use of dual antiplatelet therapy beyond a
12-month period in patients receiving drug-eluting stents have not been clearly established …

Background—The risks and benefits of long-term dual antiplatelet therapy remain unclear.
Methods and Results—This prospective, multicenter, open-label, randomized comparison …

Objectives: This study sought to evaluate the long-term cost effectiveness of a clopidogrel
loading strategy before percutaneous coronary intervention (PCI) followed by continued …

Background Clopidogrel and aspirin are the most commonly used antiplatelet therapies for
percutaneous coronary intervention (PCI). We assessed the effect of various clopidogrel and …

Aim This open-label, randomized, and multicentre trial tested the hypothesis that, on a
background of aspirin, continuing clopidogrel would be superior to stopping clopidogrel at …

ContextFollowing percutaneous coronary intervention (PCI), short-term clopidogrel therapy
in addition to aspirin leads to greater protection from thrombotic complications than aspirin …

BACKGROUND: The optimal duration of dual antiplatelet therapy after percutaneous
coronary intervention (PCI) is unknown. Incremental reductions in the risk of major adverse …